Alemtuzumab With or Without Methotrexate and Mercaptopurine in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia

NCT00089349 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

NIH

Sponsor class

Conditions

Recurrent Childhood Acute Lymphoblastic Leukemia

Interventions

BIOLOGICAL: alemtuzumab
DRUG: methotrexate
DRUG: mercaptopurine

Sponsor

National Cancer Institute (NCI)